ClinicalTrials.gg
TerminatedNCT01552798Tarot HeadacheUpdated Dec 19, 2018

Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache

A Phase 3 interventional study of Acetylsalicylic acid (Aspirin, BAY1019036) and Acetaminophen in Headache, sponsored by Bayer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 324 studies in Headache with a site in United States — 51 open to participants now, 63 under way, 5 of them phase 3. Headache · United States.

Enrollment
243rd of 276
9 · median 64
Started
2012
with 18 others
Phase 3
46 of 324
1 open now
Registered
92nd of 324
by date

Among the 324 studies in Headache with a site in United States, this one is the 243rd largest by enrollment of the 276 interventional ones that give a count, is one of 19 that started in 2012, is one of 46 in phase 3, and was the 92nd registered.

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

51 of the 324 studies in Headache with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Headache with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.

03

Conditions studied

  • Headache

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers ages 18-65 years old
  • History of an onset of tension type headaches before age 50
  • Experiencing over the last year ≥ 4 tension type headaches of at least moderate intensity per month and with the majority of headaches lasting greater than three hours, that meet commonly recognized criteria for diagnosis per the International Headache Society
  • History of response to treatment with over-the-counter (OTC) analgesics
  • Understand the pain rating scales (as judged by the trial coordinator)
  • Present with at least moderate headache pain on a 0-10 point numerical rating scale (a score of at least 4 on an 11 point scale ranging from 0 to 10) at the Treatment Visit
  • Onset of pain within three hours of the Treatment Visit
  • Confirmation by a physician of acute tension type headache symptoms as described by the International Headache Society diagnostic criteria

Exclusion criteria

Exclusion Criteria:

  • History of to aspirin, salicylates, other NSAIDs, acetaminophen, and similar pharmacological agents or components of the products, including the placebo
  • Use of any immediate release analgesic/anti-pyretic within four hours or use of any sustained release or long acting analgesic/anti-pyretic within 12 hours proceeding administration of Investigational Product
  • Presence of symptoms that are consistent with menstrual headache or migraine headache as described by the International Headache Society diagnostic criteria
  • History of migraine headaches more than once per month
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the trial in the judgment of the Investigator
  • Current or past history of bleeding disorder(s)
  • History of gastrointestinal bleeding or perforation, related to previous Nonsteroidal Anti-inflammatory Drugs (NSAID) therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
  • Recent head or neck trauma (within 2 weeks)
  • Current use of blood thinning (anticoagulant), low dose aspirin, or drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Acetylsalicylic acid (Aspirin, BAY1019036)

  • Active comparator
    Arm 2

    Drug: Acetaminophen

  • Placebo comparator
    Arm 3

    Drug: Placebo

Interventions

  • 2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets

  • 2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets

  • DrugPlacebo

    2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets

06

What researchers measure

Primary outcomes

  1. Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)

    Time frame: Up to 2 hours post-dose

Secondary outcomes

  1. Time to first perceptible relief

    Is defined as the time when the subject presses the first stopwatch

    Time frame: Up to 2 hours post-dose

  2. Time to first perceptible relief confirmed

    The subjects would meet this outcome if they answer "yes" when asked directly after stopping the first stopwatch, if they marked a "1" on the relief pain scale or if they stopped the 2nd stop watch.

    Time frame: Up to 2 hours post-dose

  3. Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)

    Time frame: At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication

  4. Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)

    Time frame: At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication

  5. Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)

    Time frame: Up to 1 hour

  6. Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)

    Time frame: Up to 2 hours

  7. Summed time weighted total pain relief scores over first hour (TOTPAR0-1)

    Time frame: Up to 1 hour

  8. Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)

    Time frame: Up to 2 hours

  9. Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)

    Time frame: Up to 1 hour

  10. Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)

    Time frame: Up to 2 hours

  11. Time to first intake of rescue medication

    Time frame: Up to 2 hours

  12. Cumulative proportion of subjects taking rescue medication by time point

    Time frame: Up to 2 hours

  13. Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent

    Time frame: At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier

  14. Safety variable will be summarized using descriptive statistic based on adverse events collection

    Time frame: Up to 5 days post-dose

07

Study locations

1 site
  • Westside Family Medical Center
    Kalamazoo, Michigan 49009, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2012 to primary completion in Jun 2012, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 13, 2012
StartActual
Mar 12, 2012
Primary completionActual
Jun 4, 2012
CompletionActual
Jun 4, 2012
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01552798
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Mar 12, 2012
Primary completion
Jun 4, 2012
Completion
Jun 4, 2012
Last update
Dec 19, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion